Profound Dermal and SubQ Cartridges for the Treatment of Cellulite

• ClinicalTrials.gov Identifier: NCT03078647
• Recruitment Status: Completed
• First Posted: March 13, 2017
• Results First Posted: June 18, 2019
• Last Update Posted: June 25, 2019
• Sponsor: Syneron Medical
• Information provided by (Responsible Party): Syneron Medical

Study Description

Brief Summary:

Clinical Study to Evaluate the Performance of the Profound System for the Treatment of Cellulite.

Condition or disease	Intervention/treatment	Phase
Cellulite	Device: Profound	Not Applicable

Detailed Description:

Up to 60 healthy female volunteers, seeking cellulite treatment, 18 to 60 years of age from up to 3 investigational sites.

Prospective, open-label, baseline-controlled, two arms, randomized, clinical study to evaluate the Profound device using the Dermal and SubQ Cartridges for minimally-invasive treatment of the upper thighs and buttocks cellulite appearance.

The treatment areas of the study subjects will be divided into two arms:

1. Arm 1 - the upper thigh/buttock on the left or right side of the body will undergo a single Profound treatment utilizing the Dermal and SubQ Cartridges
2. Arm 2 - the contralateral upper thigh/buttock side of the body will undergo a single Profound treatment utilizing the SubQ Cartridge only.

Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 31 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Clinical Study to Evaluate the Safety and Efficacy Performance of the Profound System Using the Dermal and Sub-dermal (SubQ) Cartridges for the Treatment of Cellulite
• Actual Study Start Date: September 13, 2017
• Actual Primary Completion Date: November 2, 2018
• Actual Study Completion Date: January 31, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Profound treatment to small areas; Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms	Device: Profound; The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.

Outcome Measures

Primary Outcome Measures :

1. Improvement in Global Aesthetic Appearance of Cellulite in Treated Areas, as Assessed by Study Investigator Evaluations [ Time Frame: 1,3 and 6 months post-treatment ]

   Evaluate the improvement in global aesthetic appearance of cellulite in treated areas following a single dermal and/or subcutaneous treatment with Profound, as assessed by study investigators at 1,3 and 6 months post treatment visit. Investigators used the following scale: 0=No Change; 1= 1-24% improvement; 2=25-49% improvement; 3=50-74% improvement; 4=75-100% improvement.

   The analysis calculates the improvement over 25% (grades 2-4)

Secondary Outcome Measures :

1. Improvement in Skin Tightening/Laxity in Treated Areas, as Assessed by Study Investigator Evaluations [ Time Frame: 1, 3 and 6 months post treatment visit. ]

   Evaluate the improvement in skin tightening in treated areas following a single dermal and/or subcutaneous treatment with Profound, as assessed by study investigators at 1 and 6 months post treatment visit. Investigators used the following scale: (0) No tightening/firmness; (1) Slightly visible tightening/firmness; (2) Visible tightening/firmness; (3) Very visible tightening/firmness.

   The analysis calculates the skin tightening improvement graded: (2) Visible tightening/firmness and (3) Very visible tightening/firmness

2. Investigator Satisfaction - by Questionnaire [ Time Frame: 1, 3, and 6 months post-treatment visit ]

   Evaluate Investigator satisfaction at 1, 3, and 6 months post-treatment visit, using a satisfaction scale [(-2) Very dissatisfied, (-1) Dissatisfied, (0) No opinion, (1) Satisfied, (2) Very satisfied].

   The analysis quantify investigator satisfaction (grades 1-2)

3. Subject Satisfaction and Improvement - by Questionnaire [ Time Frame: 1, 3, and 6 months post-treatment visit ]

   Evaluate subject satisfaction at 1, 3, and 6 months post-treatment visit, using a satisfaction and improvement scale [(-2) Very dissatisfied, (-1) Dissatisfied, (0) No opinion, (1) Satisfied, (2) Very satisfied].

   The analysis quantify subject satisfaction (grades 1-2)

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Signed informed consent to participate in the study.
2. Female subjects, ≥ 18 and ≤ 60 years of age at the time of enrollment
3. Fitzpatrick Skin Type I to VI.
4. Subjects seeking treatment of cellulite in the upper thighs and buttocks areas.
5. Subject cellulite stage II or III as graded using Nurnberger-Muller scale classification (Appendix III).
6. Not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
7. Negative urine pregnancy test as tested prior to each treatment and at the last visit for women of child bearing potential (e.g. not menopause).
8. General good health confirmed by medical history and skin examination of the treated area.
9. Willing to receive the proposed Profound treatment.
10. Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
11. Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.

Exclusion Criteria:

1. Subject cellulite stage 0 or I as graded using Nurnberger-Muller scale classification (Appendix III).
2. Subject had surgery or any other procedure for cellulite in the last 6 months.
3. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
4. Known allergy to lidocaine or epinephrine or antibiotics.
5. Active malignancy or history of malignancy in the past 5 years.
6. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
7. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the Physician would interfere with the anesthesia, treatment, or healing process).
8. Having a known anti-coagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
9. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
10. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen.
11. History of significant lymphatic drainage problems.
12. History of cancer which required lymph node biopsy or dissection.
13. Suffering from significant skin conditions in treatment areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions, hidradenitis, or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
14. History of keloid scarring, abnormal wound healing and / or prone to bruising.
15. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
16. Use of isotretinoin (Accutane) within 6 months of treatment or during the study.
17. Subject on systemic corticosteroid therapy 6 months prior to and throughout the course of the study.
18. Dysplastic nevi in the area to be treated.
19. Participation in a study of another device or drug within 3 month prior to enrollment or during this study.
20. Subject has palpable lymphadenopathy at any visit. Standard palpation techniques will be used.
21. Subjects with history of severe edema.
22. As per the Investigator's discretion, any physical or mental condition that might make it unsafe for subject to participate in this study.

Contacts and Locations

Locations

United States, New York

Macrene Alexiades

New York, New York, United States, 10028

United States, North Carolina

Girish Munavalli

Charlotte, North Carolina, United States, 28270

Sponsors and Collaborators

Syneron Medical

Investigators

• Principal Investigator: Girish Munavalli, MD; Laser & Vein Specialists of the Carolinas

  Study Documents (Full-Text)

Documents provided by Syneron Medical:

Study Protocol and Statistical Analysis Plan  [PDF] November 17, 2017

More Information

Publications:

Rawlings AV. Cellulite and its treatment. Int J Cosmet Sci. 2006 Jun;28(3):175-90. doi: 10.1111/j.1467-2494.2006.00318.x.

Rossi AB, Vergnanini AL. Cellulite: a review. J Eur Acad Dermatol Venereol. 2000 Jul;14(4):251-62. Review.

Alexiades M, Berube D. Randomized, blinded, 3-arm clinical trial assessing optimal temperature and duration for treatment with minimally invasive fractional radiofrequency. Dermatol Surg. 2015 May;41(5):623-32. doi: 10.1097/DSS.0000000000000347.

Alexiades M, Munavalli G, Goldberg D, Berube D. Prospective Multicenter Clinical Trial of a Temperature-Controlled Subcutaneous Microneedle Fractional Bipolar Radiofrequency System for the Treatment of Cellulite. Dermatol Surg. 2018 Oct;44(10):1262-1271. doi: 10.1097/DSS.0000000000001593.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Alexiades M, Munavalli GS. Single Treatment Protocol With Microneedle Fractional Radiofrequency for Treatment of Body Skin Laxity and Fat Deposits. Lasers Surg Med. 2021 Oct;53(8):1026-1031. doi: 10.1002/lsm.23397. Epub 2021 Mar 25.

• Responsible Party: Syneron Medical
• ClinicalTrials.gov Identifier: NCT03078647
• Other Study ID Numbers: DHF21711
• First Posted: March 13, 2017
• Results First Posted: June 18, 2019
• Last Update Posted: June 25, 2019
• Last Verified: June 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Cellulite; Skin Manifestations